自愈水凝胶
细胞外基质
骨肉瘤
肿瘤微环境
间质细胞
生物医学工程
化学
免疫组织化学
材料科学
癌症研究
球体
明胶
顺铂
恶性肿瘤
计算机科学
原子力显微镜
纳米技术
生物物理学
肿瘤进展
病理
癌细胞
共域化
荧光寿命成像显微镜
蛋白质组
非线性弹性
计算生物学
一级和二级抗体
阿霉素
作者
William Humble,Wiktor J. Zywicki,Enrico Lucarelli,Ania Naila Guerrieri,Francesca Taraballi,Gianluca Cidonio,Claudia Di Bella,Carmine Onofrillo,Andrea J. O’Connor,Serena Duchi
摘要
Osteosarcoma (OS) remains a rare, aggressive primary bone malignancy for which therapeutic progress has been limited for several decades. Three-dimensional (3D) tissue-engineered models can better reproduce the tumor microenvironment than monolayer cultures; however, their routine use is often constrained by low-throughput workflows and reliance on destructive analytical endpoints. Here, we present FOS3D, a fluorescence-enabled OS model based on gelatin methacryloyl hydrogels incorporating stable green fluorescent protein (GFP)-expressing tumor cells. By varying polymer concentration and photo-crosslinking duration, hydrogels spanning compressive moduli of approximately 5-50 kPa were generated, covering stiffness ranges reported for OS stromal environments. Whole-well fluorescence scanning enabled rapid, non-destructive quantification of proliferation in intact constructs and showed correlation with DNA and metabolic assays. Integration with light-sheet microscopy further enabled volumetric imaging of tumor organization, revealing time-dependent changes in spatial distribution. Transcriptional profiling and immunohistochemistry confirmed microenvironment-driven adaptations associated with extracellular matrix remodeling, stemness, and drug-resistance pathways. Finally, GFP-based longitudinal monitoring enabled chemotherapeutic screening of cisplatin and doxorubicin across two OS cell lines, capturing dose-dependent responses and the increased treatment tolerance characteristic of 3D cultures. Collectively, FOS3D provides a scalable fluorescence-enabled toolkit for high-content characterization and drug-response profiling of OS in physiologically relevant 3D environments.
科研通智能强力驱动
Strongly Powered by AbleSci AI